Evofem Biosciences Inc., a women's health innovator, announced its financial results for the first quarter ending March 31, 2025. The company reported net income attributable to common stockholders of $1.0 million, a significant improvement from the net loss of $4.9 million recorded in the first quarter of 2024. This translates to a net income of $0.01 per basic share for the first quarter of 2025, compared to a net loss of $(0.16) per basic share in the same period last year. Evofem's first quarter net sales were lower, as anticipated, due to the high level of PHEXXI stocking orders in the fourth quarter of 2024 and large wholesale orders for SOLOSEC. The company recorded income from operations of $0.3 million, contrasting with a loss from operations of $2.8 million in the prior year quarter. Significant updates include a strategic move to reduce manufacturing costs for PHEXXI® vaginal gel by partnering with Windtree Therapeutics, Inc. This partnership involves a new contract manufacturer that can decrease PHEXXI's cost of goods sold by 55% to 60%. Additionally, Evofem raised $1.5 million in net proceeds from the sale of senior subordinated convertible notes and warrants to Aditxt. As of March 31, 2025, the company had cash, cash equivalents, and restricted cash totaling $1.1 million, compared to $0.7 million at the end of December 2024. The second quarter of 2025 began strongly, with April marking the highest sales month for PHEXXI since November 2023, driven by robust underlying orders and solid prescription growth for both PHEXXI and SOLOSEC. Evofem aims to maintain its track record of year-over-year net sales growth since the launch of PHEXXI in 2020.